Shahar KeinanChief Scientific Officer, Cloud Pharmaceuticals
Shahar Keinan is the Chief Scientific Officer and co-founder of Cloud Pharmaceuticals. She has over 20 years of extensive experience in the field of computational and theoretical chemistry. Shahar has received a Ph.D. in theoretical chemistry from The Hebrew University of Jerusalem and has numerous papers and presentations in the fields of in-silico drug design and discovery, as well as molecular materials design and computational methods development. |
Eric MartinDirector, Computational Chemistry, Novartis
Eric Martin has a Ph.D. in physical organic chemistry from Yale University. He has worked in computational drug design and herbicide design for over 30 years. Eric is best known for starting the now widely practiced field of combinatorial library design. He is currently developing novel methodologies for two areas of drug discovery: rational oral bioavailability design and protein-family virtual screening (PFVS). The former guides improvement of oral exposure during lead optimization by applying global sensitivity analysis to physiologically-based pharmacokinetics simulations (GSA of PBPK). PFVS computer models achieve accuracy comparable to experimental high throughput screening by combining all historical activity data from entire protein families, work for which Eric was awarded the lifetime title of Novartis Leading Scientist. |
